Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kahnert K, Kauffmann-Guerrero D, Huber RM. SCLC-State of the art and what does the Future have in Store? Clin Lung Cancer. 2016;17(5):325–33.

Article  PubMed  Google Scholar 

Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(36):5311–20.

Article  PubMed  Google Scholar 

Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–56.

Article  CAS  PubMed  Google Scholar 

Fuentes N, Silva Rodriguez M, Silveyra P. Role of sex hormones in lung cancer. Exp Biol Med (Maywood). 2021;246(19):2098–110.

Article  CAS  PubMed  Google Scholar 

Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev. 2005;19(6):643–64.

Article  CAS  PubMed  Google Scholar 

Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14(18):5731–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biernacka A, Tsongalis PD, Peterson JD, de Abreu FB, Black CC, Gutmann EJ, et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 2016;209(5):195–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Elife. 2015;4:e06907.

Article  PubMed  PubMed Central  Google Scholar 

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-Mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 2018;124:53–64.

Article  PubMed  Google Scholar 

Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139–48.

Article  CAS  PubMed  Google Scholar 

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated non-small-cell Lung Cancer. N Engl J Med. 2020;383(18):1711–23.

Article  CAS  PubMed  Google Scholar 

Cascone T, William WN Jr., Weissferdt A, Leung CH, Lin HY, Pataer A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):786–95.

Article  CAS  PubMed  Google Scholar 

Goul C, Peruzzo R, Zoncu R. The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease. Nat Rev Mol Cell Biol. 2023. https://doi.org/10.1038/s41580-023-00641-8.

Article  PubMed  Google Scholar 

Chantranupong L, Scaria SM, Saxton RA, Gygi MP, Shen K, Wyant GA, et al. The CASTOR Proteins Are Arginine Sensors for the mTORC1 pathway. Cell. 2016;165(1):153–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saxton RA, Chantranupong L, Knockenhauer KE, Schwartz TU, Sabatini DM. Mechanism of arginine sensing by CASTOR1 upstream of mTORC1. Nature. 2016;536(7615):229–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li T, Wang X, Ju E, da Silva SR, Chen L, Zhang X, et al. RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation. Nat Commun. 2021;12(1):1055.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li T, Ju E, Gao SJ. Kaposi sarcoma-associated herpesvirus miRNAs suppress CASTOR1-mediated mTORC1 inhibition to promote tumorigenesis. J Clin Invest. 2019;129(8):3310–23.

Article  PubMed  PubMed Central  Google Scholar 

Li T, Gao SJ. Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection. Cell Biosci. 2021;11(1):176.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Villaruz LC, Jones H, Dacic S, Abberbock S, Kurland BF, Stabile LP, et al. ATM protein is deficient in over 40% of lung adenocarcinomas. Oncotarget. 2016;7(36):57714–25.

Article  PubMed  PubMed Central  Google Scholar 

Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, et al. Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med. 1996;335(4):233–41.

Article  CAS  PubMed  Google Scholar 

Ragavan M, Patel MI. The evolving landscape of sex-based differences in lung cancer: a distinct disease in women. Eur Respir Rev. 2022;31:163.

Article  Google Scholar 

Wang BY, Huang JY, Cheng CY, Lin CH, Ko J, Liaw YP. Lung cancer and prognosis in Taiwan: a population-based cancer registry. J Thorac Oncol. 2013;8(9):1128–35.

Article  PubMed  Google Scholar 

Jeon DS, Kim HC, Kim SH, Kim TJ, Kim HK, Moon MH, et al. Five-year overall survival and prognostic factors in patients with Lung Cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Res Treat. 2023;55(1):103–11.

Article  PubMed  Google Scholar 

Wang X, Ricciuti B, Nguyen T, Li X, Rabin MS, Awad MM, et al. Association between Smoking History and Tumor Mutation Burden in Advanced Non-small Cell Lung Cancer. Cancer Res. 2021;81(9):2566–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dogan S, Shen R, Ang DC, Johnson ML, D’Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18(22):6169–77.

Article  CAS  PubMed